Jieke

Jieke Biopharmaceutical is a Chinese biotechnology company focused on the development and commercialization of high-end recombinant protein therapeutics, particularly in the field of hematology. The company's lead program is a recombinant human coagulation factor VIIa (rhFVIIa), which is designed to treat bleeding episodes in patients with hemophilia and other rare bleeding disorders. Jieke Biopharmaceutical operates advanced manufacturing facilities in Zhejiang province, adhering to international GMP standards to support its clinical pipeline and future commercial supply. By targeting the high-barrier market for coagulation factors, the company aims to provide more accessible treatment options for patients with rare blood diseases in China and emerging markets.